

Drug-resistant *Acinetobacter baumannii*: From molecular mechanisms to potential therapeutics (Review)

HAO-JIA WU^{1*}, ZHI-GANG XIAO^{2*}, XIAO-JUAN LV³⁻⁵, HAI-TANG HUANG³⁻⁵,
CHU LIAO³⁻⁵, CHEN-YANG HUI³⁻⁵, YUE XU¹ and HENG-FEI LI³⁻⁵

¹Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei 430065; ²Department of Orthopedics, Hubei Provincial Hospital of Traditional Chinese Medicine; ³Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine; ⁴Department of Infection, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, Hubei 430061; ⁵Department of Infection, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, Hubei 430074, P.R. China

Received October 6, 2022; Accepted February 24, 2023

DOI: 10.3892/etm.2023.11908

Abstract. Bacterial drug resistance is increasingly becoming an important problem that needs to be solved urgently in modern clinical practices. Infection caused by *Acinetobacter baumannii* is a serious threat to the life and health of patients. The drug resistance rate of *Acinetobacter baumannii* strains is increasing, thus research on the drug resistance of *Acinetobacter baumannii* has also seen an increase. When patients are infected with drug-resistant *Acinetobacter baumannii*, the availability of suitable antibiotics commonly used in clinical practices is becoming increasingly limited and the prognosis of patients is worsening. Studying the molecular mechanism of the drug resistance of *Acinetobacter baumannii* is fundamental to solving the problem of drug-resistant *Acinetobacter baumannii* and potentially other 'super bacteria'. Drug resistance mechanisms primarily include enzymes, membrane proteins, efflux pumps and beneficial mutations. Research on the underlying mechanisms provides a theoretical basis for the use and development of antibiotics and the development of novel treatment methods.

Contents

1. Introduction
2. Epidemiology of *Acinetobacter baumannii*
3. Features of *Acinetobacter baumannii*
4. Mechanisms of drug resistance and their clinical implications
5. Conclusions and future perspectives

1. Introduction

The problem of bacterial resistance is ever increasingly becoming a serious threat to humans, and superbugs now account for >540,000 infections and nearly 14,000 deaths each year in the United States alone (1). The discovery of penicillin and the synthesis and application of antibacterial sulfonamides in the 20th century have greatly eased the suffering of patients, but the uncontrolled abuse of antibiotics in the past 50 years has made 'ESKAPE' (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter species*) increasingly resistant and treatment of these bacterial infections has become increasingly difficult (2). Amongst these superbugs, drug-resistant *Acinetobacter baumannii* infections are notably serious with the increasing number of its infections (3). The purpose of this review is to highlight the molecular mechanisms underlying drug resistance in *Acinetobacter baumannii* and to summarize novel ideas for solving the problem of drug resistance.

2. Epidemiology of *Acinetobacter baumannii*

The history of *Acinetobacter* can be traced back to 1991 when the Danish microbiologist Martinus Willem Beijerinck discovered *Micrococcus calcoaceticus* (4). The first identification analysis of *Acinetobacter* species was based on their biochemical characterization, while the use of molecular

Correspondence to: Professor Heng-Fei Li, Department of Hepatology, Hubei Key Laboratory of The Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Room 4, Garden Hill, Wuchang, Wuhan, Hubei 430061, P.R. China
E-mail: 26877767@qq.com

*Contributed equally

Key words: *Acinetobacter baumannii*, drug resistance, treatment, antibiotics

methods, in particular DNA-DNA hybridization, identified at least 33 genetically distinct species of *Acinetobacter* (5). In the majority of laboratories, *Acinetobacter baumannii*, *Acinetobacter pittii* and *Acinetobacter nosocomialis* are difficult to distinguish (6), as they possess closely related microbiological characteristics. Hence, this review will use *Acinetobacter baumannii* in the comprehensive sense to refer to these three species collectively. The identification of *Acinetobacter baumannii* can be distinguished by multilocus sequence typing, as it utilizes 16S ribosomal RNA as well as conserved regions of seven housekeeping genes: *gltA*, *gyrB*, *gdhB*, *recA*, *cpn60*, *gpi* and *rpoD* (7).

Acinetobacter baumannii, once even considered benign, is now considered a global threat in healthcare settings, and it is gaining resistance at an unforeseen rate (8). In early 2019, the World Health Organization stated that *Acinetobacter baumannii* is considered the most dangerous multidrug-resistant bacteria (9). Until the early 1970s, *Acinetobacter* strains showed susceptibility to most antibiotics (10). Extensive resistance to carbapenem antibiotics is considered to be a sign of extensively drug-resistant bacteria, and carbapenem-resistant *Acinetobacter baumannii* is now causing serious problems in Asia and the Americas. In Southern Europe, Middle East and Asia and North Africa ~90% of clinical isolates of *Acinetobacter baumannii* are resistant to carbapenems (11). Globally, ~45% of *Acinetobacter baumannii* isolates are multi-drug resistant, with >70% of isolates in Latin America and the Middle East exhibiting multi-drug resistance (12).

3. Features of *Acinetobacter baumannii*

Acinetobacter baumannii was considered a low-virulence bacterium in the past, and its severity was not taken seriously until the mid-1990s (13). In recent years, following the continual increase in its virulence and the difficulty in treating infections due to drug resistance has resulted in increased attention from public health bodies (14). *Acinetobacter baumannii* is a Gram-negative bacterium that is a strictly aerobic, catalase-positive, oxidase-negative and non-lactose-fermentative opportunistic pathogen (6). *Acinetobacter baumannii* is almost everywhere such as waterbodies, soil, mines, crude oil, sewage, sludge, solid surfaces, human skin and wild animals (11), it is not only difficult to treat but also difficult to eliminate. This is due to its excellent anti-starvation (15), anti-desiccating (16), seasonal adaptation and high-temperature resistance properties (17), in addition to reduced sensitivity to disinfectants (18) and biofilm protection (19). Drug-resistant *Acinetobacter baumannii* is one of the most common pathogens of nosocomial infections, especially in immunocompromised patients and in ICU wards (20). In addition, prolonged use of antibiotics, major surgery, severe burns and immunosuppression increase the risk of *Acinetobacter baumannii* infections (21). *Acinetobacter baumannii* infections can lead to ventilator-associated pneumonia, bacteremia, urinary tract infection and meningitis (22). The overall prevalence of multi-drug-resistant strains of *Acinetobacter baumannii* in patients with hospital-acquired pneumonia and ventilator-associated pneumonia is estimated at 79.9%, with an overall mortality rate that can be as high as 56.2% (23).

4. Mechanisms of drug resistance and their clinical implications

With improvements in research equipment and methods in the fields of modern medicine and microorganisms, the mechanisms underlying *Acinetobacter baumannii* drug resistance have become increasingly understood. The known mechanisms of *Acinetobacter baumannii* drug resistance and potential developmental directions are summarized in Table I and Fig. 1, with treatment options being listed in Table II. Below, an in-depth summary of the known body of knowledge on *Acinetobacter baumannii* drug resistance is provided.

β -lactams. Since the first β -lactam antibiotic was discovered (penicillin), they have become incorporated as a core part of clinical practice as treatments for various bacterial infections; β -lactam antibiotics are chosen as the antibacterial drug of choice (16). β -lactam antibiotics act on the peptidoglycan in the cell walls of fungi and bacteria, and they work by suppressing bacterial cell division or inducing bacterial rupture (24). However, bacteria can produce β -lactamase to enzymatically break down β -lactam antibiotics, which is the most prevalent mechanism of drug resistance. In the Ambler classification, β -lactamases can be grouped into one of four classes (A-D) according to the sequences of the amino acids that make up the enzyme (25).

Ambler class A enzymes. The serine β -lactamases of molecular class A are the most important enzymatic source of both natural and acquired resistance to β -lactams, particularly in *Acinetobacter baumannii* (26). TEM, SHV, CTX-M and KPC are the primary Ambler class A enzymes (27). TEM, CTX-M and KPC can hydrolyze penicillin, cephalosporin and carbapenem. Additionally, the use of antibiotics allows these enzymes to evolve and develop stronger drug resistance (28).

Ambler class B enzymes. Zinc-dependent metallo- β -lactamases (MBLs) are typically associated with gene cassettes of integrons and thus spread easily amongst bacteria (29). MBLs are classified into 3 subclasses. B1 and B3 are catalytically inactivated by two Zn^{2+} ions, and B2 is catalytically inactivated by one Zn^{2+} ion (14). NDM, VIM, SPM and IMP are the primary Ambler class B enzymes. The presence of the plasmid enables the rapid spread of the MBL gene, and the spread of NDM-1 is closely associated with drug resistance in *Acinetobacter baumannii* (30,31). Since the discovery of NDM-1 in India, over 24 NDM variants have been identified (32). NDM enzymes, composed of 270 amino acids, hydrolyze most β -lactams (including carbapenems) but not monobactams. However, NDM enzymes cannot be countered by clinically available β -lactamase inhibitors, including avibactam, clavulanate, sulbactam and tazobactam (33). Studies have shown that the percentage of NDM-1-positive isolates tends to be the highest, and *Acinetobacter baumannii* with the NDM gene show resistance to ampicillin (34). The acquisition of the NDM-1 gene is likely facilitated by the action of *Tn125* (35).

Ambler class C enzymes. *Acinetobacter*-derived cephalosporinases (ADCs) are responsible for resistance to cephalosporin antibiotics. ADC is the primary Ambler class C enzyme (27). ADC-mediated drug resistance is achieved through overexpression of ADC, and this overexpression

Table I. Mechanisms of resistance employed by *Acinetobacter baumannii*.

Antibiotic	Resistance mechanism	Enzyme or target	Key point	(Refs.)
β -lactams	β -lactamases	Ambler class A	TEM, SHV, CTX-M, KPC	(26-28)
		Ambler class B	NDM, VIM, SIM, IMP	(30,31)
		Ambler class C	AmpC, ADC	(27,36,37)
		Ambler class D	OXA	(7,39-41,43,44)
	Permeability lesions	Outer membrane porin	CarO	(46)
Tetracyclines	Efflux pump overactivity	RND pump	OmpA	(46-48)
			AdeABC	(49,50)
	Efflux pump overactivity	RND pump	AdeABC, AdeIJK	(79,80)
Quinolones	Target mutation	Tet pump	TetA, TetG	(81)
		DNA gyrase	GyrA	(88)
		DNA topoisomerase IV	ParC	(88)
	Efflux pump overactivity	RND pump	AdeABC	(89)
Aminoglycosides	Drug inactivating enzymes	Aminoglycoside modifying enzymes	aadB, apa6, aadA, aacc1	(92)
	Target mutation	16s RNA methylase genes	armA	(93)
	Efflux pump overactivity	RND pumps	AdeABC	(94)
Polymyxins	Target mutation	Abnormalities of lipid A and LPS	PmrC, PmrB, lpx gene	(68-71)

itself is achieved through an ISAbal insertion sequence, which is located in close proximity to the genes which confer resistance (36). The production of AmpC β -lactamases may be either chromosomally mediated or plasmid-mediated. AmpC β -lactamases are not inhibited by clavulanic acid, but are inhibited by cloxacillin or boronic acid (37). *Acinetobacter baumannii* can rapidly develop drug resistance due to the chemical similarity of the molecules between β -lactamase inhibitors and β -lactams, thus β -lactamase inhibitors, such as sulbactam and clavulanic acid, eventually become ineffective against *Acinetobacter baumannii* (38).

Ambler class D enzymes. Amongst the D-type β -lactamases, oxacillinase (OXA) is associated with resistance to carbapenems (39). The primary reason for carbapenem resistance is the presence of oxacillinase, which belongs to class D Ambler β -lactamases. To date, >400 OXA enzymes encoded by chromosomal or plasmid-localized genes have been characterized (40). The hydrolytic activity of OXA-type groups is more potent for oxacillin than benzylpenicillin; however, OXA-type enzymes are not considered extended-spectrum β -lactamases (ESBLs) as they do not hydrolyze broad-spectrum cephalosporins (7). The OXA-23 enzyme is encoded by a chromosomal gene or located on a plasmid, and it confers resistance to several antibiotics including ticarcillin, meropenem, amoxicillin and imipenem. The OXA-40 enzyme can hydrolyze penicillin; however, its ability to hydrolyze cephalosporins and carbapenems is weak, and it is

resistant to inhibitors such as tazobactam, sulbactam, clavulanic acid and NaCl. The OXA-51 gene is generally non-transferable, encoded by chromosomal DNA. Clavulanic acid, tazobactam, or NaCl effectively blocks the activity of OXA-51. OXA-58 is found on a non-transferable 30k plasmid. When this plasmid is incorporated into the gene chain of *Acinetobacter baumannii*, carbapenem susceptibility is reduced (7). Because of certain insertion sequences, such as ISAbal, ISAbal25 and ISAbal825, the overproduction ADC and OXA-51 confer high-level resistance to third- and fourth-generation cephalosporins (41). Carbapenem antibiotics, as the most commonly used antibiotics for nosocomial infections in the world, have successfully led to the enhancement of drug resistance in microorganisms such as *Acinetobacter baumannii* (16). The prevalence of carbapenem-resistant *Acinetobacter Baumannii* (CRAB) is increasing rapidly in many countries and regions, and this has complicated treatment choices (42). Carbapenem resistance is primarily mediated by B-type and D-type. The most common OXA-type carbapenemases include OXA-23, OXA-24, OXA-48, OXA-51 and OXA-58. Among them, OXA-23, OXA-24, OXA-48 and OXA-58 are acquired carbapenemases, whereas OXA-51 is intrinsic to *Acinetobacter baumannii* (43). The genes encoding these enzymes are regulated by upstream insertion sequences (IS), specifically ISAbal, ISAbal2, ISAbal3, ISAbal9 and IS18. They lead to increased resistance to carbapenems through the expression of the blaOXA gene. In addition to OXA




Figure 1. Schematic diagram of the resistance mechanisms employed by *Acinetobacter Baumannii*. Common resistance mechanisms include β -lactamase hydrolysis, mutations in target genes, overexpression of efflux pumps, drug inactivation of enzymes, and permeability impairment caused by outer membrane porins.

carbapenemases, the transferable MBL family, including VIM, IMP, GIM, SIM and NDM enzymes are also associated with the drug-resistant phenotype of *Acinetobacter baumannii* (44).

Other aspects aside from enzymes. Outer membrane proteins (OMPs) in general are β -barrel-shaped monomeric or trimeric porins that allow the diffusion of small molecules into and out of the periplasmic space of Gram-negative bacteria (45). The outer membrane of *Acinetobacter baumannii* contains several OMPs, including OmpA, CarO, OprD-like OMPs, Omp 33-36 kDa, AbuO, TolB, DcaP, Oma87/BamA, NmRmpM, CadF and OprF, amongst others. OMP has multiple functions, which confers bacterial resistance to threats such as harsh environments and antibiotics (46). OmpA is the most abundant outer membrane porin in *Acinetobacter baumannii*, and it functions by binding to efflux pumps and expelling antimicrobial compounds from the periplasm (47). OmpA increases the sensitivity of *Acinetobacter baumannii* to nalidixic acid, chloramphenicol, aztreonam, imipenem and meropenem, this feature is inseparable from its C-terminal region and *Acinetobacter baumannii* peptidoglycan (PG) coupling regulates outer membrane vesicle (OMV) stability (48). In addition, OmpA also actively siphons extracellular drugs to mediate antibiotic resistance and isogenic mutants, which in turn leads to a loss of cell wall integrity that sensitizes bacteria to colistin and

also confers virulence (46). The outer membrane protein CarO is a carbapenem drug resistance-related OMP encoded by the CarO gene. CarO is divided into two subgroups, namely CarOa and CarOb. Facing different environments and hosts, the rapid adaptation of *Acinetobacter baumannii* results in alterations of the CarO gene (46). The resistance-nodulation-cell division (RND) efflux pump system is also associated with resistance in *Acinetobacter baumannii*. The efflux pump can extrude a variety of antibacterial agents, reducing the accumulation of antibiotics (49). The overexpression of adeABC plays an important role in acquired resistance to antibiotics. Cefepime, cefpirome and cefotaxime are the β -lactams most affected by the adeABC efflux system (50). Moreover, penicillin-binding protein 7/8 increases susceptibility to complement and contributes either directly or indirectly to serum resistance (51).

Novel options for resistance against β -lactam-based antibiotics. In recent years, researchers have found that the amino acid sequence of OmpA is highly conserved (>89%) in various clinical isolates, and OmpA mediates the adhesion and invasion of *Acinetobacter baumannii* to epithelial cells. OmpA can stimulate the innate immune response and induce biofilm formation, thus OmpA is a potential therapeutic target, although it has been shown that OmpA is not necessary for bacterial survival (22). It has been

Table II. Treatment options for drug-resistant *Acinetobacter baumannii* infections.

Resistance to antibiotics	Treatment (for reference only)	(Refs.)
β-lactams	Cefiderocol	(53-55)
	CCCP and imipenem/cefepime	(56)
	Quercetin and imipenem	(57)
	DBOs and sulbactam	(59)
	QPX7728 and meropenem/ceflorazone/piperacillin/cefepime	(60)
	Ampicillin and sulbactam	(61)
	Berberine hydrochloride and sulbactam	(63)
	Piper betle and antibiotics	(65)
	Vaccines (preventative)	(58,62)
	Iron control	(52)
Tetracyclines	Cilantro oil combined with piperacillin or cefoperazone	(64)
	KBP-7072 and omadacycline	(83)
	Omadacycline and sulbactam	(84)
Quinolones	Tetracycline and D-LANA-14	(85)
	Ciprofloxacin/imipenem and Mentha longifolia/Menthol	(90)
	Ciprofloxacin and Na-3DH-DCA/Na-3DH-CDCA	(91)
Aminoglycosides	Tobramycin and colistin	(97)
	Aminoglycosides and L-lysine	(96)
	Colistin and Silver nanoparticles	(74)
	Macolacin	(75)
	Polymyxin B and rifampicin/imipenem/meropenem/tigecycline	(76)
Biofilm	<i>Scutellaria barbata</i>	(77)
	Myrtenol and antibiotics	(102)
	Polymyxin B/E and azithromycin	(103)
	Illicium verum Hook	(104)
	Phage	(105)
	Antimicrobial photodynamic therapy	(106)
	Antimicrobial peptides	(107)

shown that increased iron content enhances OmpA protein expression in *Acinetobacter baumannii*, and strains with high OmpA protein expression are more aggressive, thus iron control strategies can be used in the management of *Acinetobacter baumannii* to reduce drug resistance (52). Cefiderocol, a member of the β-lactam antibiotics family, inhibits the synthesis of Gram-negative bacterial cell walls by binding to penicillin-binding proteins. However, due to its siderophore-like properties, it can enter the periplasmic space in bacteria and exhibits high stability to various β-lactamases such as AmpC and ESBLs (53,54). In an *in vitro* study, Cefiderocol was shown to be effective against OXA-23, OXA-40 and OXA-58. as well as NDM and IMP-producing *Acinetobacter baumannii* isolates (55). Efflux pumps are an important part of drug resistance. The efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone can enhance the susceptibility of *Acinetobacter baumannii* to imipenem and cefepime (56). Equally effective efflux pump inhibitors include Quercetin, particularly when combined with imipenem, and it has a significant inhibitory effect on NDM and mexB/adeB (57). *Acinetobacter baumannii* vaccine studies has shown that the most effective vaccines tend to be multiplexed (consisting of outer membrane

vesicles, bacterial ghosts, or multi-subunits) and are usually composed of antigens from OmpA, OmpW, OmpK and Omp22 (58). For resistance to carbapenem antibiotics, the development of β-lactamase inhibitors has shown favorable results. β-lactamase inhibitor diazabicyclooctanes combined with sulbactam restored the sensitivity of sulbactam to carbapenem-resistant *Acinetobacter* (59). QPX7728 is a boronic acid-lactamase inhibitor, which was shown to inhibit class A ESBLs, class B carbapenemases (NDM, VIM and IMP), class C and class D (OXA-23), and it enhanced its action against carbapenem-resistant *Acinetobacter baumannii* when combined with meropenem, ceflorazone, piperacillin and cefepime (60). Additionally, the combination of ampicillin and sulbactam (18 g per day) is an effective regimen for reducing the mortality of patients with CRAB (61). In addition, in terms of vaccine development, vaccines against BauA and OmpA that are vital virulence factors in pathogenicity of *Acinetobacter baumannii* play a certain role and combination of these antigens that can bind BauA and OmpA enhanced clearance of bacteria in liver and spleen (62). TCM ingredients can also be used to treat drug-resistant *Acinetobacter baumannii*. Possibly due to the synergistic action with antibiotics on efflux pump AdeB, Berberine

hydrochloride combined with sulbactam can improve the antibacterial efficiency against *Acinetobacter baumannii* (63). Cilantro oil combined with piperacillin or cefoperazone can enhance the efficacy of the latter (64); however, the mechanism underlying the improved efficacy when combined needs to be determined. Other TCMs such as Piper betle combined with antibiotics are also worthy of research (65).

Polymyxins. The resistance of *Acinetobacter baumannii* to Polymyxins include: i) modification of the lipid A structure, ii) complete loss of Lipopolysaccharide (LPS) via mutations in the genes that synthesize lipid A, iii) reduction in the expression of cofactors involved in LPS synthesis, and iv) downregulation of proteins that participate in the export and/or stabilization of outer membrane precursors (66). LPS is part of the outer membrane of bacteria. Polymyxins inhibit bacterial membranes after binding to LPS, interact with lipid A of the bacterial outer membrane, and cause cell permeability and death by destroying membrane phospholipids. However, polymyxins antibiotics take a long time to work, and the use of colistin may increase the probability of nephrotoxic and neurotoxic complications (67). Colistin resistance in *Acinetobacter baumannii* is primarily caused by mutations in the PmrBTCS sensor kinase resulting in overexpression of PmrC. It has been shown that by knocking out the colistin PmrA mutant, its MICs is reduced by 64 to 1,024-fold, thereby restoring sensitivity to polymyxins (68). In *Acinetobacter baumannii*, various mutations and small fragments in the PmrB region are the primary cause of colistin resistance, and the most common PmrB mutation is A138T (69). The mutation of PmrA and PmrB of *Acinetobacter baumannii* can lead to resistance to polymyxins, and its virulence and fitness are also reduced. In addition, impaired virulence and fitness are also related to the *lpx* gene (70). Mutations in *lpxA*, *lpxC* and *lpx* affect lipid A synthesis. These spontaneous mutations include single-base changes, large deletions, and insertions of IS elements, all of which contribute to the high resistance exhibited by *Acinetobacter baumannii* (71). In addition, the induction of endogenous production of reactive oxygen species (ROS) by polymyxins, thus leading to oxidative killing of bacteria via hydroxyl radicals. *Acinetobacter baumannii* via inhibiting the formation of hydroxyl radicals attenuates polymyxin killing (72).

In the face of increasing drug resistance, it is a novel direction to identify new targets for use in combination with multiple drugs, such as the development of inhibitors against the targets of the modified bacterial outer membrane LPS two-component signal transduction system (73). Solving the problem of drug resistance should not only rely on antibiotics, instead, it may be favorable to combine current therapeutics with silver nanoparticles. Silver nanoparticles can penetrate microbial cell walls and alter cell membrane structure; this may reduce the MIC by 8-32X when used in combination with colistin (74). In addition, macolacin, a chemically synthesized substance that targets the plasmid-borne polymyxin resistance gene *mcr-1*, is also effective for Gram-negative pathogens expressing *mcr-1* including *Acinetobacter baumannii* (75). The combination of polymyxin B with imipenem, meropenem, tigecycline

and rifampicin in the treatment of *Acinetobacter baumannii* was superior to any of these alone, and the combination with rifampicin had the best effect (76). In terms of TCMs, the extract of *Scutellaria barbata* was shown to exhibit a good inhibitory effect on *Acinetobacter baumannii*, and the mechanism may be related to ROS (77), and the combination of *Scutellaria barbata* and polymyxin may have unexpected effects.

Tetracyclines. Tigecycline, a unique semi-synthetic antibacterial agent of the glycylcycline class, is derived from tetracycline and designed to overcome common resistance mechanisms to tetracycline (78). Its mechanism of action is to inhibit bacterial growth by binding to the bacterial 30S ribosome and blocking the entry of tRNA, ultimately preventing protein synthesis. Although tigecycline circumvents resistance mechanisms of tetracycline, *Acinetobacter baumannii* can acquire tigecycline resistance through overexpression of efflux pumps, particularly AdeABC, and modification of the tigecycline-binding site in the ribosome through *rpsJ* mutations (79). Likewise, the *adeIJK* of the RND efflux pump confers *Acinetobacter baumannii* resistance against tetracycline antibiotics (80). It has been shown that *Acinetobacter baumannii* expressing tetracycline transporter gene (*tetA*) have significantly increased MICs for tetracycline and tigecycline. *Acinetobacter baumannii* that express *tetG* also show resistance to these tetracyclines in addition to drug resistance to tigecycline (81). Although there are also genetic studies showing that the increased resistance of strains induced by tigecycline can be recovered, this also indicates that the use of tigecycline therapy may increase the risk of multidrug-resistant gaining additional resistance (82).

It has been shown that third-generation tetracyclines (aminomethylcycline) KBP-7072 and omadacycline overcome efflux and ribosomal protection resistance mechanisms observed during tetracycline resistance, highlighting a novel direction for the development of tetracycline-based antibiotics (83). In addition, Omadacycline in combination with sulbactam was shown to be synergistic and bactericidal against 80% of isolates (84). A study showed that D-lysine conjugated aliphatic norspermidine analogue bearing tetradecanoyl chain (also known as D-LANA-14) increased the permeability of cell membranes. When D-LANA-14 was combined with tetracycline and other inactive antibiotics, it exhibited synergistic activity against *Acinetobacter baumannii* (85).

Quinolones. Through gene knockout studies, it has been shown that the transporter *AbaQ* is primarily involved in the extrusion of quinolones from *Acinetobacter baumannii* (86). Resistance to quinolones has also been attributed to spontaneous mutations in genes, including DNA gyrase and topoisomerase IV. This leads to high levels of resistance to quinolones in *Acinetobacter baumannii* (87). Changes in antibiotic target sites are an important mechanism of bacterial resistance, that manifests through random point mutations with a minimal impact on bacterial cell homeostasis. In *Acinetobacter baumannii*, the most common mechanism of resistance is fluoroquinolone resistance, which is acquired by spontaneous mutations in the *gyrA*, *gyrB* and *parC* genes which encode gyrase and topoisomerase IV (88). The existence

of the efflux pump adeABC is still an important cause of drug resistance in *Acinetobacter baumannii* (89).

A newer study shows that *Mentha longifolia* and Menthol can facilitate the entry of material into the cell membrane of bacteria and mitochondria, thereby facilitating the inhibition of the adeABC efflux pump in *Acinetobacter baumannii*. When *Mentha longifolia* and Menthol are combined with ciprofloxacin and imipenem, it can significantly reduce the MIC for *Acinetobacter baumannii* (90). Bile salt derivatives, Na-3DH-DCA and Na-3DH-CDCA, have synergistic effects on certain strains of *Acinetobacter baumannii* when used in combination with ciprofloxacin, highlighting a potential future direction (91).

Aminoglycosides. The most common aminoglycoside resistance gene in *Acinetobacter baumannii* is aadB (42%), followed by apa6 (26%), while aadA1 (18%), with aaccl (12%) being rare (92). The armA gene is an effective factor for the resistance of *Acinetobacter baumannii* to aminoglycosides; the gene encodes 16S rRNA methylase, which leads to the limited access of aminoglycosides into the bacterial ribosomes, and furthermore leads to high-level aminoglycoside resistance (HLAR) to gentamicin, brumycin, amikacin and kanamycin (93). In addition, AdeABC has a restrictive effect in reducing the susceptibility of *Acinetobacter baumannii* to aminoglycoside antibiotics (94).

It has been shown that strains with a single well-defined resistance mechanism lack cross-resistance to gentamicin, amikacin, tobramycin and prazomycin (95). Thus, the cross-use of aminoglycosides is a temporary solution. Additionally, L-lysine combats drug-resistant *Acinetobacter baumannii* by increasing the transmembrane ΔpH difference which in-turn increases the bacterial proton motive force and stimulates the uptake of aminoglycoside antibiotics (96). The combination of antibiotics is another method of treatment. Tobramycin and colistin can be used to treat or eradicate *Acinetobacter baumannii* by reducing the expression of the universal stress protein (uspA) (97).

Biofilm. Several pathogens, including *Acinetobacter Baumannii*, produce biofilms in response to dry conditions, nutrient shortages, resistance to antibiotics, and other challenges (98). The formation of *Acinetobacter Baumannii* is associated with the Quorum sensing pathway, two-component system signal transduction pathway, cyclic-di-GMP signaling and the capsular polysaccharide synthesis pathway. Biofilm-associated proteins such as Bap in *Acinetobacter Baumannii* also serve a vital role in biofilm (99). Several studies have shown that csuE, pgaB, epsA, ptk, bfmS and the ompA biofilm-related genes are involved in biofilm formation (99,100). However, resistance due to biofilms is specific and these genes are not direct factors for the resistance of *Acinetobacter Baumannii* (101). Thus, additional research is required to clarify the specific mechanisms involved.

Myrtenol is an important dicyclic monoterpene alcohol, which inhibits the growth of biofilms by affecting the adhesion factors associated with biofilms and improves the sensitivity of certain antibiotics to *Acinetobacter baumannii*. Myrtenol has the potential to be used in combination with antibiotics (102). The combination of polymyxin B or E with azithromycin can

inhibit biofilm formation (103). These studies suggest that the combination of antibiotics is still a valuable method for the treatment of multiple drug resistant infections. The extract of star anise (*Illicium verum Hook.*) has a significant inhibitory effect on biofilm, which does not affect the growth of cells. The underlying mechanism may involve the disruption of the cell membrane of bacteria due to the lipophilic nature of the extract (104). In addition, phage (105), antimicrobial photodynamic therapy (106) and antimicrobial peptides (107) are seen as non-antibiotic therapies with significant potential for the future.

5. Conclusions and future perspectives

Bacterial infections are the cause of several diseases and can aggravate already present diseases as well. The development of drug resistance caused by its unique physiological characteristics makes infections caused by drug-resistant *Acinetobacter baumannii* considerably more difficult to treat. Therefore, a deeper understanding on the drug resistance mechanisms is required to improve our armamentarium against said infections. At present, differing combinations of antibiotics is the easiest and most effective way to manage infections. However, novel therapeutics will likely be required going forward as drug resistance increases. Thus, robust clinical trials will also be required for any novel therapeutics. That is, to manage the ever-increasing drug resistance, improved drugs, newer treatment technologies and alternative treatment methods are required.

Acknowledgements

The authors would like to thank Dr Chen-Xia Lu (Department of Hepatology, Hubei Key Laboratory of the Theory and application research of liver and kidney in traditional Chinese medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, China) and Dr Hui Zhu (Department of Clinical College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China) for their assistance in the development of this review.

Funding

The preparation of this manuscript was funded by the Hubei Province Traditional Chinese Medicine Infectious Disease Discipline Construction Project and the Inheritance and Development Project of Traditional Chinese medicines (grant no. Z155080000004).

Availability of data and materials

Not applicable.

Authors' contributions

HJW and ZGX designed the subject of review. HFL revised the article. HJW, ZGX, XJL, HTH, CYH, CL, YX and HFL participated in writing and reviewing the manuscript. All

authors have read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Mojica MF, Rossi MA, Vila AJ and Bonomo RA: The urgent need for metallo- β -lactamase inhibitors: An unattended global threat. *Lancet Infect Dis* 22: e28-e34, 2022.
- Khan SN and Khan AU: Breaking the spell: Combating multi-drug resistant 'superbugs.' *Front Microbiol* 7: 174, 2016.
- Boral B, Unaldi Ö, Ergin A, Durmaz R and Eser ÖK; Acinetobacter Study Group: A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant *Acinetobacter baumannii* infections in intensive care units with clinical and environmental features. *Ann Clin Microbiol Antimicrob* 18: 19, 2019.
- Torres HA, Vázquez EG, Yagüe G and Gómez JG: Multidrug resistant *Acinetobacter baumannii*: Clinical update and new highlights. *Rev Esp Quimioter* 23: 12-19, 2010 (In Spanish).
- Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G, Álvarez-Hernández DA, *et al*: *Acinetobacter baumannii* resistance: A real challenge for clinicians. *Antibiotics* (Basel) 9: 205, 2020.
- Ayoub Moubareck C and Hammoudi Halat D: Insights into *Acinetobacter baumannii*: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. *Antibiotics* (Basel) 9: 119, 2020.
- Ibrahim S, Al-Saryi N, Al-Kadmy IMS and Aziz SN: Multidrug-resistant *Acinetobacter baumannii* as an emerging concern in hospitals. *Mol Biol Rep* 48: 6987-6998, 2021.
- Harding CM, Hennon SW and Feldman MF: Uncovering the mechanisms of *Acinetobacter baumannii* virulence. *Nat Rev Microbiol* 16: 91-102, 2018.
- Bagińska N, Pichlak A, Górski A and Jończyk-Matysiak E: Specific and selective bacteriophages in the fight against multidrug-resistant *Acinetobacter baumannii*. *Virol Sin* 34: 347-357, 2019.
- Roy S, Chowdhury G, Mukhopadhyay AK, Dutta S and Basu S: Convergence of biofilm formation and antibiotic resistance in *Acinetobacter baumannii* infection. *Front Med (Lausanne)* 9: 793615, 2022.
- Ma C and McClean S: Mapping global prevalence of *Acinetobacter baumannii* and recent vaccine development to tackle it. *Vaccines* (Basel) 9: 570, 2021.
- Colquhoun JM and Rather PN: Insights into mechanisms of biofilm formation in *Acinetobacter baumannii* and implications for uropathogenesis. *Front Cell Infect Microbiol* 10: 253, 2020.
- Bergogne-Bérézin E and Towner KJ: *Acinetobacter* spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 9: 148-165, 1996.
- Ramirez MS, Bonomo RA and Tolmasky ME: Carbapenemases: Transforming *Acinetobacter baumannii* into a yet more dangerous menace. *Biomolecules* 10: 720, 2020.
- Chapartegui-González I, Lázaro-Díez M, Bravo Z, Navas J, Icardo JM and Ramos-Vivas J: *Acinetobacter baumannii* maintains its virulence after long-time starvation. *PLoS One* 13: e0201961, 2018.
- Nguyen M and Joshi SG: Carbapenem resistance in *Acinetobacter baumannii*, and their importance in hospital-acquired infections: a scientific review. *J Appl Microbiol* 131: 2715-2738, 2021.
- Kim YA, Kim JJ, Won DJ and Lee K: Seasonal and temperature-associated increase in community-onset *Acinetobacter baumannii* complex colonization or infection. *Ann Lab Med* 38: 266-270, 2018.
- Guo J and Li C: Molecular epidemiology and decreased susceptibility to disinfectants in carbapenem-resistant *Acinetobacter baumannii* isolated from intensive care unit patients in central China. *J Infect Public Health* 12: 890-896, 2019.
- Weinberg SE, Villedieu A, Bagdasarian N, Karah N, Teare L and Elamin WF: Control and management of multidrug resistant *Acinetobacter baumannii*: A review of the evidence and proposal of novel approaches. *Infect Prev Pract* 2: 100077, 2020.
- Oh DH, Kim YC, Kim EJ, Jung IY, Jeong SJ, Kim SY, Park MS, Kim A, Lee JG and Paik HC: Multidrug-resistant *Acinetobacter baumannii* infection in lung transplant recipients: Risk factors and prognosis. *Infect Dis (Lond)* 51: 493-501, 2019.
- Martín-Aspas A, Guerrero-Sánchez FM, García-Colchero F, Rodríguez-Roca S and Girón-González JA: Differential characteristics of *Acinetobacter baumannii* colonization and infection: Risk factors, clinical picture, and mortality. *Infect Drug Resist* 11: 861-872, 2018.
- Nie D, Hu Y, Chen Z, Li M, Hou Z, Luo X, Mao X and Xue X: Outer membrane protein A (OmpA) as a potential therapeutic target for *Acinetobacter baumannii* infection. *J Biomed Sci* 27: 26, 2020.
- Kyriakidis I, Vasileiou E, Pana ZD and Tragiannidis A: *Acinetobacter baumannii* antibiotic resistance mechanisms. *Pathogens* 10: 373, 2021.
- Sawa T, Kooguchi K and Moriyama K: Molecular diversity of extended-spectrum β -lactamases and carbapenemases, and antimicrobial resistance. *J Intensive Care* 8: 13, 2020.
- Tsivkovski R, Totrov M and Lomovskaya O: Biochemical characterization of QPX7728, a new ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases. *Antimicrob Agents Chemother* 64: e00130-20, 2020.
- Philippon A, Jacquier H, Ruppé E and Labia R: Structure-based classification of class A beta-lactamases, an update. *Curr Res Transl Med* 67: 115-122, 2019.
- Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y and Spencer J: β -Lactamases and β -lactamase inhibitors in the 21st century. *J Mol Biol* 431: 3472-3500, 2019.
- Palzkill T: Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC β -lactamases. *Front Mol Biosci* 5: 16, 2018.
- Nikibakhsh M, Firoozeh F, Badmasti F, Kabir K and Zibaei M: Molecular study of metallo- β -lactamases and integrons in *Acinetobacter baumannii* isolates from burn patients. *BMC Infect Dis* 21: 782, 2021.
- Amin M, Navidifar T, Saleh Shooshtari F and Goodarzi H: Association of the genes encoding metallo- β -lactamase with the presence of integrons among multidrug-resistant clinical isolates of *Acinetobacter baumannii*. *Infect Drug Resist* 12: 1171-1180, 2019.
- López C, Ayala JA, Bonomo RA, González LJ and Vila AJ: Protein determinants of dissemination and host specificity of metallo- β -lactamases. *Nat Commun* 10: 3617, 2019.
- Ejaz H, Alzahrani B, Hamad MFS, Abosalif KOA, Junaid K, Abdalla AE, Elamir MYM, Aljaber NJ, Hamam SSM and Younas S: Molecular analysis of the antibiotic resistant NDM-1 gene in clinical isolates of enterobacteriaceae. *Clin Lab* 66, 2020.
- Wu W, Feng Y, Tang G, Qiao F, McNally A and Zong Z: NDM metallo- β -lactamases and their bacterial producers in health care settings. *Clin Microbiol Rev* 32: e00115-18, 2019.
- Junaid K: Molecular diversity of NDM-1, NDM-5, NDM-6, and NDM-7 variants of new delhi metallo- β -lactamases and their impact on drug resistance. *Clin Lab* 67, 2021.
- Jiang L, Yu Y, Zeng W, Guo J, Lv F, Wang X, Liu X and Zhao Z: Whole-genome analysis of New Delhi metallo-beta-lactamase-1-producing *Acinetobacter haemolyticus* from China. *J Glob Antimicrob Resist* 20: 204-208, 2020.
- Ingti B, Upadhyay S, Hazarika M, Khyriem AB, Paul D, Bhattacharya P, Joshi SR, Bora D, Dhar D and Bhattacharjee A: Distribution of carbapenem resistant *Acinetobacter baumannii* with bla_{ADC-30} and induction of ADC-30 in response to beta-lactam antibiotics. *Res Microbiol* 171: 128-133, 2020.

37. Said HS, Benmahmod AB and Ibrahim RH: Co-production of AmpC and extended spectrum beta-lactamases in cephalosporin-resistant *Acinetobacter baumannii* in Egypt. *World J Microbiol Biotechnol* 34: 189, 2018.
38. Bouza AA, Swanson HC, Smolen KA, VanDine AL, Taracila MA, Romagnoli C, Caselli E, Prati F, Bonomo RA, Powers RA and Wallar BJ: Structure-based analysis of boronic acids as inhibitors of acinetobacter-derived cephalosporinase-7, a unique class C β -lactamase. *ACS Infect Dis* 4: 325-336, 2018.
39. Porbaran M, Tahmasebi H and Arabestani M: A comprehensive study of the relationship between the production of β -lactamase enzymes and iron/siderophore uptake regulatory genes in clinical isolates of *Acinetobacter baumannii*. *Int J Microbiol* 2021: 5565537, 2021.
40. Monem S, Furmanek-Błaszczak B, Łupkowska A, Kuczyńska-Wiśnik D, Stojowska-Swędryńska K and Laskowska E: Mechanisms protecting *Acinetobacter baumannii* against multiple stresses triggered by the host immune response, antibiotics and outside-host environment. *Int J Mol Sci* 21: 5498, 2020.
41. Lupo A, Haenni M and Madec JY: Antimicrobial Resistance in *Acinetobacter* spp. and *Pseudomonas* spp. *Microbiol Spectr* 16, 2018.
42. Hamidian M and Nigro SJ: Emergence, molecular mechanisms and global spread of carbapenem-resistant *Acinetobacter baumannii*. *Microb Genom* 5: e000306, 2019.
43. Shi X, Wang H, Wang X, Jing H, Duan R, Qin S, Lv D, Fan Y, Huang Z, Stirling K, *et al*: Molecular characterization and antibiotic resistance of *Acinetobacter baumannii* in cerebrospinal fluid and blood. *PLoS One* 16: e0247418, 2021.
44. Ibrahim ME: Prevalence of *Acinetobacter baumannii* in Saudi Arabia: Risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance. *Ann Clin Microbiol Antimicrob* 18: 1, 2019.
45. Slusky JSG and Dunbrack RL Jr: Charge asymmetry in the proteins of the outer membrane. *Bioinformatics* 29: 2122-2128, 2013.
46. Uppalapati SR, Sett A and Pathania R: The outer membrane proteins OmpA, CarO, and OprD of *Acinetobacter baumannii* confer a two-pronged defense in facilitating its success as a potent human pathogen. *Front Microbiol* 11: 589234, 2020.
47. Tsai YK, Liou CH, Lin JC, Fung CP, Chang FY and Siu LK: Effects of different resistance mechanisms on antimicrobial resistance in *Acinetobacter baumannii*: A strategic system for screening and activity testing of new antibiotics. *Int J Antimicrob Agents* 55: 105918, 2020.
48. Skerniškytė J, Karazijaitė E, Lučiūnaitė A and Sužiedėlienė E: OmpA protein-deficient *Acinetobacter baumannii* outer membrane vesicles trigger reduced inflammatory response. *Pathogens* 10: 407, 2021.
49. Zhang Y, Fan B, Luo Y, Tao Z, Nie Y, Wang Y, Ding F, Li Y and Gu D: Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among *Acinetobacter baumannii* strains with different carbapenem susceptibility. *BMC Infect Dis* 21: 841, 2021.
50. Kim CM, Park G, Ko YJ, Kang SH and Jang SJ: Relationships between relative expression of RND efflux pump genes, H33342 efflux activity, biofilm-forming activity, and antimicrobial resistance in *Acinetobacter baumannii* clinical isolates. *Jpn J Infect Dis* 74: 499-506, 2021.
51. Badmasti F, Habibi M, Firoozeh F, Fereshteh S, Bolourchi N and Goodarzi NN: The combination of CipA and PBP-7/8 proteins contribute to the survival of C57BL/6 mice from sepsis of *Acinetobacter baumannii*. *Microb Pathog* 158: 105063, 2021.
52. Liu H, Cao CY, Qiu FL, Huang HN, Xie H, Dong R, Shi YZ and Hu XN: Iron-rich conditions induce OmpA and virulence changes of *Acinetobacter baumannii*. *Front Microbiol* 12: 725194, 2021.
53. Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R and Rybak MJ: Cefiderocol: A novel siderophore cephalosporin against multidrug-resistant gram-negative pathogens. *Pharmacotherapy* 40: 1228-1247, 2020.
54. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, *et al*: Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. *Drugs* 79: 271-289, 2019.
55. Isler B, Doi Y, Bonomo RA and Paterson DL: New treatment options against carbapenem-resistant *Acinetobacter baumannii* infections. *Antimicrob Agents Chemother* 63: e01110-18, 2018.
56. Sanchez-Carbonel A, Mondragón B, López-Chegne N, Peña-Tuesta I, Huayan-Dávila G, Blitchtein D, Carrillo-Ng H, Silva-Caso W, Aguilar-Luis MA and Del Valle-Mendoza J: The effect of the efflux pump inhibitor carbonyl cyanide m-chlorophenylhydrazone (CCCP) on the susceptibility to imipenem and cefepime in clinical strains of *Acinetobacter baumannii*. *PLoS One* 16: e0259915, 2021.
57. Pal A and Tripathi A: Quercetin potentiates meropenem activity among pathogenic carbapenem-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. *J Appl Microbiol* 127: 1038-1047, 2019.
58. Gellings PS, Wilkins AA and Morici LA: Recent advances in the pursuit of an effective *Acinetobacter baumannii* vaccine. *Pathogens* 9: 1066, 2020.
59. Pasteran F, Cedano J, Baez M, Alborno E, Rapoport M, Osteria J, Montaña S, Le C, Ra G, Bonomo RA, *et al*: A new twist: The combination of sulbactam/avibactam enhances sulbactam activity against carbapenem-resistant *Acinetobacter baumannii* (CRAB) isolates. *Antibiotics (Basel)* 10: 577, 2021.
60. Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH and Leibovici L: New β -lactam- β -lactamase inhibitor combinations. *Clin Microbiol Rev* 34: e00115-20, 2020.
61. Bartal C, Rolston KVI and Neshier L: Carbapenem-resistant *Acinetobacter baumannii*: Colonization, infection and current treatment options. *Infect Dis Ther* 11: 683-694, 2022.
62. Tamehri M, Rasooli I, Pishgahi M, Jahangiri A, Ramezanalizadeh F and Banisaeed Langroodi SR: Combination of BauA and OmpA elicit immunoprotection against *Acinetobacter baumannii* in a murine sepsis model. *Microb Pathog* 173: 105874, 2022.
63. Li X, Song Y, Wang L, Kang G, Wang P, Yin H and Huang H: A potential combination therapy of berberine hydrochloride with antibiotics against multidrug-resistant *Acinetobacter baumannii*. *Front Cell Infect Microbiol* 11: 660431, 2021.
64. Duarte A, Ferreira S, Silva F and Domingues FC: Synergistic activity of coriander oil and conventional antibiotics against *Acinetobacter baumannii*. *Phytomedicine* 19: 236-238, 2012.
65. Herman A and Herman AP: Herbal products and their active constituents used alone and in combination with antibiotics against multidrug-resistant bacteria. *Planta Med* 89: 168-182, 2023.
66. Lima WG, Alves MC, Cruz WS and Paiva MC: Chromosomally encoded and plasmid-mediated polymyxins resistance in *Acinetobacter baumannii*: A huge public health threat. *Eur J Clin Microbiol Infect Dis* 37: 1009-1019, 2018.
67. Nasr P: Genetics, epidemiology, and clinical manifestations of multidrug-resistant *Acinetobacter baumannii*. *J Hosp Infect* 104: 4-11, 2020.
68. Trebosc V, Gartenmann S, Tötzel M, Lucchini V, Schellhorn B, Pieren M, Lociuero S, Gitzinger M, Tigges M, Bumann D and Kemmer C: Dissecting colistin resistance mechanisms in extensively drug-resistant *Acinetobacter baumannii* clinical isolates. *mBio* 10: e01083-19, 2019.
69. Nurtop E, Bayındır Bilman F, Menekse S, Kurt Azap O, Gönen M, Ergonul O and Can F: Promoters of Colistin Resistance in *Acinetobacter baumannii* Infections. *Microb Drug Resist* 25: 997-1002, 2019.
70. Wang Y, Luo Q, Xiao T, Zhu Y and Xiao Y: Impact of polymyxin resistance on virulence and fitness among clinically important gram-negative bacteria. *Engineering* 13: 178-185, 2022.
71. Moffatt JH, Harper M and Boyce JD: Mechanisms of polymyxin resistance. *Adv Exp Med Biol* 1145: 55-71, 2019.
72. Nang SC, Azad MAK, Velkov T, Zhou Q and Li J: Rescuing the last-line polymyxins: Achievements and challenges. *Pharmacol Rev* 73: 679-728, 2021.
73. Mohapatra SS, Dwibedy SK and Padhy I: Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions. *J Biosci* 46: 85, 2021.
74. Khaled JM, Alharbi NS, Siddiqi MZ, Alobaidi AS, Nauman K, Alahmedi S, Almazyed AO, Almosallam MA and AlJurayyan AN: A synergic action of colistin, imipenem, and silver nanoparticles against pandrug-resistant *Acinetobacter baumannii* isolated from patients. *J Infect Public Health* 14: 1679-1685, 2021.
75. Wang Z, Koirala B, Hernandez Y, Zimmerman M, Park S, Perlín DS and Brady SF: A naturally inspired antibiotic to target multidrug-resistant pathogens. *Nature* 601: 606-611, 2022.
76. Zhang H, Zhu Y, Yang N, Kong Q, Zheng Y, Lv N, Chen H, Yue C, Liu Y, Li J and Ye Y: In vitro and in vivo Activity of combinations of polymyxin B with other antimicrobials against carbapenem-resistant *Acinetobacter baumannii*. *Infect Drug Resist* 14: 4657-4666, 2021.

77. Tsai CC, Lin CS, Hsu CR, Chang CM, Chang IW, Lin LW, Hung CH and Wang JL: Using the Chinese herb *Scutellaria barbata* against extensively drug-resistant *Acinetobacter baumannii* infections: In vitro and in vivo studies. *BMC Complement Altern Med* 18: 96, 2018.
78. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z and Maleki F: Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: Narrative review. *Eur J Clin Microbiol Infect Dis* 41: 1003-1022, 2022.
79. Jo J and Ko KS: Tigecycline heteroresistance and resistance mechanism in clinical isolates of *Acinetobacter baumannii*. *Microbiol Spectr* 9: e0101021, 2021.
80. Zhang Z, Morgan CE, Bonomo RA and Yu EW: Cryo-EM determination of eravacycline-bound structures of the ribosome and the multidrug efflux pump AdeJ of *Acinetobacter baumannii*. *mBio* 12: e0103121, 2021.
81. Foong WE, Wilhelm J, Tam H-K and Pos KM: Tigecycline efflux in *Acinetobacter baumannii* is mediated by TetA in synergy with RND-type efflux transporters. *J Antimicrob Chemother* 75: 1135-1139, 2020.
82. Cheng J, Kesavan DK, Vasudevan A, Cai W, Wang H, Su Z, Wang S and Xu H: Genome and transcriptome analysis of *A. baumannii*'s 'Transient' increase in drug resistance under tigecycline pressure. *J Glob Antimicrob Resist* 22: 219-225, 2020.
83. Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, *et al.*: In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized *Acinetobacter baumannii* species complex isolates. *Antimicrob Agents Chemother* 64: e02375-19, 2020.
84. Abbey T, Vialichka A, Jurkovic M, Biagi M and Wenzler E: Activity of omadacycline alone and in combination against carbapenem-nonsusceptible *Acinetobacter baumannii* with varying minocycline susceptibility. *Microbiol Spectr* 10: e00542-22, 2022.
85. Konai MM and Haldar J: Lysine-based small molecule sensitizes rifampicin and tetracycline against multidrug-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *ACS Infect Dis* 6: 91-99, 2020.
86. Pérez-Varela M, Corral J, Aranda J and Barbé J: Functional characterization of AbaQ, a novel efflux pump mediating quinolone resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 62: e00906-18, 2018.
87. Mohammed MA, Salim MTA, Anwer BE, Aboshanab KM and Aboulwafa MM: Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of *Acinetobacter baumannii* to fluoroquinolones. *Sci Rep* 11: 20136, 2021.
88. Vrancianu CO, Gheorghe I, Czobor IB and Chifiriuc MC: Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of *Acinetobacter baumannii*. *Microorganisms* 8: 935, 2020.
89. Nogbou ND, Nkawane GM, Ntshane K, Wairuri CK, Phofa DT, Mokgokong KK, Ramashia M, Nchabeleng M, Obi LC and Musyoki AMZ: Efflux pump activity and mutations driving multidrug resistance in *Acinetobacter baumannii* at a Tertiary Hospital in Pretoria, South Africa. *Int J Microbiol* 2021: 9923816, 2021.
90. Mahmoudi H, Shokoohizadeh L, Zare Fahim N, Mohamadi Bardebari A, Moradkhani S and Alikhani MY: Detection of adeABC efflux pump encoding genes and antimicrobial effect of *Mentha longifolia* and Menthol on MICs of imipenem and ciprofloxacin in clinical isolates of *Acinetobacter baumannii*. *BMC Complement Med Ther* 20: 92, 2020.
91. Aleksić Sabo V, Škorić D, Jovanović-Šanta S, Nikolić I, János C and Knežević P: Synergistic activity of bile salts and their derivatives in combination with conventional antimicrobial agents against *Acinetobacter baumannii*. *J Ethnopharmacol* 264: 113266, 2021.
92. Rizk M and Abou El-Khier N: Aminoglycoside resistance genes in *Acinetobacter baumannii* clinical isolates. *Clin Lab* 65, 2019.
93. Jouybari MA, Ahanjan M, Mirzaei B and Goli HR: Role of aminoglycoside-modifying enzymes and 16S rRNA methylase (ArmA) in resistance of *Acinetobacter baumannii* clinical isolates against aminoglycosides. *Rev Soc Bras Med Trop* 54: e05992020, 2021.
94. Sheikhalizadeh V, Hasani A, Ahangarzadeh Rezaee M, Rahmati-Yamchi M, Hasani A, Ghotaslou R and Goli HR: Comprehensive study to investigate the role of various aminoglycoside resistance mechanisms in clinical isolates of *Acinetobacter baumannii*. *J Infect Chemother* 23: 74-79, 2017.
95. Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, Ercan O, Petersson A, Cao S, Aboklaish AF, *et al.*: In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and *Acinetobacter baumannii*. *J Antimicrob Chemother* 74: 944-952, 2019.
96. Deng W, Fu T, Zhang Z, Jiang X, Xie J, Sun H, Hu P, Ren H, Zhou P, Liu Q and Long Q: L-lysine potentiates aminoglycosides against *Acinetobacter baumannii* via regulation of proton motive force and antibiotics uptake. *Emerg Microbes Infect* 9: 639-650, 2020.
97. Kashyap S, Kaur S, Sharma P and Capalash N: Combination of colistin and tobramycin inhibits persistence of *Acinetobacter baumannii* by membrane hyperpolarization and down-regulation of efflux pumps. *Microbes Infect* 23: 104795, 2021.
98. Law SKK and Tan HS: The role of quorum sensing, biofilm formation, and iron acquisition as key virulence mechanisms in *Acinetobacter baumannii* and the corresponding anti-virulence strategies. *Microbiol Res* 260: 127032, 2022.
99. Kaushik V, Tiwari M, Joshi R and Tiwari V: Therapeutic strategies against potential antibiofilm targets of multidrug-resistant *Acinetobacter baumannii*. *J Cell Physiol* 237: 2045-2063, 2022.
100. Donadu MG, Mazzarello V, Cappuccinelli P, Zanetti S, Madlén M, Nagy ÁL, Stájer A, Burián K and Gajdács M: Relationship between the biofilm-forming capacity and antimicrobial resistance in clinical *Acinetobacter baumannii* isolates: Results from a laboratory-based in vitro study. *Microorganisms* 9: 2384, 2021.
101. Shenkutie AM, Yao MZ, Siu GKH, Wong BKC and Leung PHM: Biofilm-induced antibiotic resistance in clinical *Acinetobacter baumannii* Isolates. *Antibiotics (Basel)* 9: 817, 2020.
102. Selvaraj A, Valliammai A, Sivasankar C, Suba M, Sakthivel G and Pandian SK: Antibiofilm and antivirulence efficacy of myrtenol enhances the antibiotic susceptibility of *Acinetobacter baumannii*. *Sci Rep* 10: 21975, 2020.
103. Meng Q, Lin F and Ling B: In vitro activity of peptide antibiotics in combination with other antimicrobials on extensively drug-resistant *Acinetobacter baumannii* in the planktonic and biofilm cell. *Front Pharmacol* 13: 890955, 2022.
104. Salem MA, El-Shiekh RA, Hashem RA and Hassan M: In vivo antibacterial activity of star anise (*Illicium verum* Hook.) extract using murine MRSA skin infection model in relation to its metabolite profile. *Infect Drug Resist* 14: 33-48, 2021.
105. Shahed-Al-Mahmud M, Roy R, Sugiokto FG, Islam MN, Lin MD, Lin LC and Lin NT: Phage ϕ AB6-borne depolymerase combats *Acinetobacter baumannii* biofilm formation and infection. *Antibiotics (Basel)* 10: 279, 2021.
106. Figueiredo-Godoi LMA, Garcia MT, Pinto JG, Ferreira-Strixino J, Faustino EG, Pedrosa LLC and Junqueira JC: Antimicrobial photodynamic therapy mediated by fotenticine and methylene blue on planktonic growth, biofilms, and burn infections of *Acinetobacter baumannii*. *Antibiotics (Basel)* 11: 619, 2022.
107. das Neves RC, Mortari MR, Schwartz EF, Kipnis A and Junqueira-Kipnis AP: Antimicrobial and antibiofilm effects of peptides from venom of social wasp and scorpion on multidrug-resistant *Acinetobacter baumannii*. *Toxins (Basel)* 11: 216, 2019.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.